MBIO vs. BPTSY, BPTS, CWBR, VRPX, ARAV, ARDS, REVB, AGRX, SXTP, and ONCO
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Biophytis (BPTSY), Biophytis (BPTS), CohBar (CWBR), Virpax Pharmaceuticals (VRPX), Aravive (ARAV), Aridis Pharmaceuticals (ARDS), Revelation Biosciences (REVB), Agile Therapeutics (AGRX), 60 Degrees Pharmaceuticals (SXTP), and Onconetix (ONCO). These companies are all part of the "pharmaceutical preparations" industry.
Biophytis (NASDAQ:BPTSY) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability, media sentiment and community ranking.
Biophytis has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.75, meaning that its stock price is 75% more volatile than the S&P 500.
In the previous week, Mustang Bio had 10 more articles in the media than Biophytis. MarketBeat recorded 13 mentions for Mustang Bio and 3 mentions for Biophytis. Biophytis' average media sentiment score of 0.56 beat Mustang Bio's score of -0.67 indicating that Mustang Bio is being referred to more favorably in the news media.
Mustang Bio has a consensus target price of $11.50, suggesting a potential upside of 3,352.42%. Given Biophytis' higher possible upside, analysts clearly believe Mustang Bio is more favorable than Biophytis.
Mustang Bio received 169 more outperform votes than Biophytis when rated by MarketBeat users.
0.1% of Biophytis shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 2.1% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Mustang Bio's return on equity of 0.00% beat Biophytis' return on equity.
Summary
Mustang Bio beats Biophytis on 7 of the 11 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
